SEC Form 4 · accession 0000891293-18-000086
CTI BIOPHARMA CORP · CTIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Adam R Craig
Officer — President and CEO · Director
Period of report
Sep 18, 2018
Accepted (ET)
Sep 20, 2018 · 4:46 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000891293
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F1 | $1.88 | Sep 18, 2018 | A | 600,000 | A | — | Sep 18, 2028 | Common Stock | 600,000 | 600,000 | D |
Explanation of responses
- F1The stock options will vest in six equal semi-annual installments over a three-year period commencing on September 18, 2018 subject to continued employment with the Company through the applicable vesting dates, such that the option will be fully vested on September 18, 2021.